Aridis Pharmaceuticals, Inc.: auditor change — Aridis Pharmaceuticals appoints Grassi & Co. as new auditor after Baker Tilly resignation

Aridis Pharmaceuticals, Inc.

Baker Tilly resigned as independent auditor effective after filing Q1 2023 10-Q.
Grassi & Co. appointed as new independent registered public accounting firm effective June 16, 2023.
Audit Committee approved the appointment; no prior consultations with Grassi on accounting matters.
No disagreements or reportable events occurred with former auditor during 2022 or Q1 2023.

item 4.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 1.0

Aridis Pharmaceuticals, Inc. engaged Grassi & Co. CPAs, P.C. as its auditor.

Action: engagement
Auditor: Grassi & Co. CPAs, P.C.

Exact text from the filing

the Company appointed Grassi & Co. CPAs, P.C. (" Grassi ") as the Company's new independent registered public accounting firm effective as of June 16, 2023.

View on SEC.gov

Browse all auditor changes →

Source: SEC EDGAR

accession 0001493152-23-022159

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.